Prognostic Impact of Human Lymphocyte Antigen (HLA) Class I Expression in Patients With Breast Cancer.
Humans
Female
Breast Neoplasms
/ immunology
Middle Aged
Histocompatibility Antigens Class I
/ metabolism
Prognosis
Aged
Adult
Biomarkers, Tumor
/ metabolism
Disease-Free Survival
Kaplan-Meier Estimate
Aged, 80 and over
Lymphocytes, Tumor-Infiltrating
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Immunohistochemistry
HLA class I
breast cancer
prognosis
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
received:
08
06
2024
revised:
07
07
2024
accepted:
08
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
28
8
2024
Statut:
ppublish
Résumé
Various biomarkers are utilized in the field of breast cancer. Human lymphocyte antigen (HLA) class I molecules have a critical role in cancer immune surveillance. Therefore, this study aimed to assess the HLA class I expression and analyze the correlation with clinicopathologic factors in breast cancer. We investigated the clinical pathology archives of 150 consecutive patients with breast cancer who underwent a curative operation at the Sapporo Medical University, Japan, from January 2012 to December 2014. Immunohistochemical staining was used to evaluate HLA class I expression and CD8-positive T cell infiltration. The Pearson χ Patients with dull/negative HLA class I had significantly poor disease-free survival (DFS) compared with those with positive HLA class I (p=0.0073). Univariate analyses revealed that pT, pN, positive lymphatic invasion, and dull/negative HLA class I were significantly associated with DFS. Multivariate analyses revealed dull/negative HLA class I as an independent poor prognostic factor (hazard ratio=2.75, 95% confidence interval=1.30-5.80, p=0.008). HLA class I expression level may have a very sensitive prognostic effect on patients with breast cancer.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Various biomarkers are utilized in the field of breast cancer. Human lymphocyte antigen (HLA) class I molecules have a critical role in cancer immune surveillance. Therefore, this study aimed to assess the HLA class I expression and analyze the correlation with clinicopathologic factors in breast cancer.
PATIENTS AND METHODS
METHODS
We investigated the clinical pathology archives of 150 consecutive patients with breast cancer who underwent a curative operation at the Sapporo Medical University, Japan, from January 2012 to December 2014. Immunohistochemical staining was used to evaluate HLA class I expression and CD8-positive T cell infiltration. The Pearson χ
RESULTS
RESULTS
Patients with dull/negative HLA class I had significantly poor disease-free survival (DFS) compared with those with positive HLA class I (p=0.0073). Univariate analyses revealed that pT, pN, positive lymphatic invasion, and dull/negative HLA class I were significantly associated with DFS. Multivariate analyses revealed dull/negative HLA class I as an independent poor prognostic factor (hazard ratio=2.75, 95% confidence interval=1.30-5.80, p=0.008).
CONCLUSION
CONCLUSIONS
HLA class I expression level may have a very sensitive prognostic effect on patients with breast cancer.
Identifiants
pubmed: 39197900
pii: 44/9/4039
doi: 10.21873/anticanres.17233
doi:
Substances chimiques
Histocompatibility Antigens Class I
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4039-4047Informations de copyright
Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.